

Attorney Docket No.: P-2507-US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): YEDGAR, Saul et al.

Examiner: O'SULLIVAN, PETER G

Serial No.: 10/627,981

Group Art Unit: 1621

Filed: July 28, 2003

Title: USE OF LIPID CONJUGATES IN THE TREATMENT OF DISEASES

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTARY INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§1.56, 1.97 and 1.98, this Information Disclosure Statement includes Form PTO-1449:

1. listing documents including patents, publications and other information for consideration by the Examiner, however, since the subject application was filed after June 30, 2003, copies of United States patents and/or United States patent application publications are not included in this information disclosure statement; and/or
2. listing documents including patents, publications and other information that have been previously cited or submitted to the Patent Office in prior application U.S. Serial No. _____, filed _____ which is properly identified and relied on for an earlier effective filing date under 35 U.S.C. 120 for consideration by the Examiner; however, in accordance with 37 C.F.R. 1.98(d), copies of such documents are not included in this information disclosure statement; and/or
3. listing documents including patents, publications, and other information for consideration by the Examiner, copies of which are included with this information disclosure statement;
4. listing other information for the Examiner's consideration which was cited in a communication from a foreign patent office in a counterpart foreign application, a copy of which is included with this information disclosure statement.

11/30/2005 MBEYENE1 00000045 503355 10627981
01 FC:1606 100.00 DR

APPLICANTS: YEDGAR, Saul et al.
SERIAL NO.: 10/627,981
FILED: July 28, 2003
Page 2

The information herein cited is only in fulfillment of Applicant(s) duty of candor in disclosing all information brought to Applicant(s) attention. This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art". If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicant(s) reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant(s) further reserve(s) the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each and every document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application and is evidence that the Examiner has considered the document.

This Information Disclosure Statement is being filed:

- I) Within three (3) months of filing the subject Application or entry of the subject Application into the national stage or before mailing of the first Office Action on the merits of the subject Application or a request for continued examination thereof, whichever event occurs last pursuant to of 37 C.F.R §1.97 (b); or
- II) After the period specified in (I) but before the mailing date of either a final Official Action under 37 C.F.R §1.113 or a notice of allowance under 37 C.F.R §1.311 whichever occurs first and;

1. the undersigned hereby states that each item of information listed on the Form PTO-1449 was either (i) cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this Information Disclosure Statement or (ii) not cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, not known to any individual designated in §1.56(c) more than three (3) months prior to the filing of this information disclosure statement; or


APPLICANTS: YEDGAR, Saul et al.
SERIAL NO.: 10/627,981
FILED: July 28, 2003

Page 3

2. the undersigned hereby authorizes the Patent Office to charge the fee in the amount of \$180.00 under 37 C.F.R. §1.17 (p) to Deposit Account 50-3355.
- III) After the period in (I) and (II) but before the payment of the issue fee and,
1. The undersigned hereby states:
 - a) that each item of information cited on the form PTO-1449 was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three (3) months prior to the filing of this Information Disclosure Statement; or
 - b) that no items of information contained in Form PTO-1449 was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; and
 2. The undersigned hereby authorizes the Patent Office to charge the Petition fee in the Amount of \$180.00 under 37 C.F.R. §1.17 (p) to Deposit Account 50-3355.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-3355.


Respectfully submitted,


Rachel Teitelbaum
Attorney/Agent for Applicant(s)
Registration No. 56,708

Dated: November 20, 2005

Pearl Cohen Zedek Latzer, LLP
10 Rockefeller Plaza, Suite 1001
New York, New York 10020
Tel: (212) 632-3480
Fax: (212) 632-3489

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
a collection of information unless it displays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/627,981
		Filing Date	July 28, 2003
		First Named Inventor	YEDGAR, Saul
		Group Art Unit	1621
		Examiner Name	O'SULLIVAN, PETER G
Sheet	1	of	2
		Attorney Docket Number	

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U S Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement: This form is estimated to take 20 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +



PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	2	of	2	Examiner Name	O'SULLIVAN, PETER G
				Attorney Docket Number	P-2507-US1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	H	ALBINI, A, IWAMOTO, Y, KLEINMAN, HK, MARTIN, GR, AARONSON, SA, KOZLOWSKI, JM AND MCEWAN, RN (1987) "A rapid in vitro assay for quantitating the invasive potential of tumor cells" <u>Cancer Res</u> 47(12):3239-45	<input type="checkbox"/>
	I	CABANAS, C AND HOGG, N (1993) "Ligand intercellular adhesion molecule 1 has a necessary role in activation of integrin lymphocyte function-associated molecule 1" <u>Proc Natl Acad Sci U S A</u> 90(12):5838-42	<input type="checkbox"/>
	J	DAN, P, DAGAN, A, KRIMSKY, M, PRUZANSKI, W, VADAS, P AND YEDGAR, S (1998) "Inhibition of type I and type II phospholipase A2 by phosphatidyl-ethanolamine linked to polymeric carriers" <u>Biochemistry</u> 37(17):6199-204	<input type="checkbox"/>
	K	GREAVES, MW AND CAMP, RD (1988) "Prostaglandins, leukotrienes, phospholipase, platelet activating factor, and cytokines: an integrated approach to inflammation of human skin" <u>Arch Dermatol Res</u> 280:S33-41.	<input type="checkbox"/>
	L	KRIMSKY, M, DAGAN, A, APTEKAR, L, LIGUMSKY, M AND YEDGAR, S (2000) "Assessment of intestinal permeability in rats by permeation of inulin-fluorescein" <u>J Basic Clin Physiol Pharmacol</u> 11(2):143-53	<input type="checkbox"/>
	M	KRIMSKY, M, YEDGAR, S, APTEKAR, L, SCHWOB, O, GOSHEN, G, GRUZMAN, A, SASSON, S AND LIGUMSKY, M (2003) "Amelioration of TNBS-induced colon inflammation in rats by phospholipase A2 inhibitor" <u>Am J Physiol Gastrointest Liver Physiol</u> 285(3):G586-92	<input type="checkbox"/>
	N	MARGOLIS-NUNNO, H, BEN-HUR, E, GOTTLIEB, P, ROBINSON, R, OETJEN, J AND HOROWITZ, B (1996) "Inactivation by phthalocyanine photosensitization of multiple forms of human immunodeficiency virus in red cell concentrates" <u>Transfusion</u> 36(8):743-50	<input type="checkbox"/>
	O	MURTHY, SN, COOPER, HS, SHIM, H, SHAH, RS, IBRAHIM, SA AND SEDERGRAN, DJ (1993) "Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin" <u>Dig Dis Sci</u> 38(9):1722-34	<input type="checkbox"/>
	P	OKAYASU, I, HATAKEYAMA, S, YAMADA, M, OHKUSA, T, INAGAKI, Y AND NAKAYA, R (1990) "A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice" <u>Gastroenterology</u> 98(3):694-702	<input type="checkbox"/>
	Q	SCHMIEL, DH AND MILLER, VL (1999) "Bacterial phospholipases and pathogenesis" <u>Microbes Infect</u> 1(13):1103-12	<input type="checkbox"/>
	R	SCHNITZER, E, PINCHUK, I, FAINARU, M, LICHTENBERG, D AND YEDGAR, S (1998) "LDL-associated phospholipase A does not protect LDL against lipid peroxidation in vitro" <u>Free Radic Biol Med</u> 24(7-8):1294-303	<input type="checkbox"/>
	S	SCHNITZER, E, YEDGAR, S, DANINO, D, TALMON, Y AND LICHTENBERG D (1999) "The interaction of hyaluronic-phosphatidylethanolamine with low density lipoprotein (LDL) and its effect on copper induced LDL oxidation" <u>Biophysical Journal</u> 76(1): Part 2.	<input type="checkbox"/>

Examiner Signature		Date Considered
--------------------	--	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Unique citation designation number ² Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement: This form is estimated to take 2 0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231